Use of newer medications for weight loss and blood sugar management has surged between 2021 and 2023, especially tirzepatide, which is sold under the brand name Mounjaro for diabetes treatment and ...

HealthDay News — After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without diabetes ...

(HealthDay News) — After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without diabetes ...

Each participant received weekly doses of tirzepatide—either 5 mg, 10 mg, or 15 mg—for three years. At the end of this period, the results were impressive. On average, participants lost ...

Tirzepatide's uptake was rapid post-launch, surpassing other GLP-1 RAs and SGLT2 inhibitors, while conventional GLMs like metformin and insulin declined. The approval of tirzepatide for type 2 ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes ...

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both ...

The trial uncovered no new safety issues. New Delhi: Taking tirzepatide drug once a week may produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight ...

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model New in vitro data demonstrates ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...